Skip to main content
. 2020 Jan 29;5(1):e000578. doi: 10.1136/esmoopen-2019-000578

Table 3.

Overall survival due to HRD status in patients with locally advanced or metastatic pancreatic cancer not treated with platinum-based chemotherapy

Study HRD Non-HRD P value
n Median OS (months) n Median OS (months)
Reiss et al 17 11 6.1 30 2.8 0.12
Pishvaian et al 29 19 9.1 114 14.4 0.11
Aung et al 31 12 8.3 ND ND
Golan et al 32 21 9.0 ND ND
Faluyi et al 33 6 7.3 ND ND
Total 69 8.3 144 12.0

HRD, homologous recombination deficiency; n, number of patients; ND, no data provided.